Skip to main content

Austedo News

Teva Announces FDA Approval of Austedo XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of Austedo

New once-daily Austedo XR regimen now approved in 6, 12, and 24 mg tablet strengths Austedo is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD)...

Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults

JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo...

Teva Announces FDA Approval of Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

JERUSALEM--(BUSINESS WIRE)--Apr. 3, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Tardive Dyskinesia, Huntington's Disease

Austedo patient information at Drugs.com